All In MedTech

Device Trial Radar · NCT03405740

Virtual E-health System for Implantable Cardioverter Defibrillators

Virtual Integrated Reliable Transformative User-driven E-health System for Implantable Cardioverter Defibrillators

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,115

Actual

Start

May 1, 2020

Primary completion

Apr 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Ratika ParkashAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cardiac Arrhythmia Network of Canada; Abbott Medical Devices; Medtronic
First posted
Jan 23, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Canadian multicenter randomized controlled trial to assess remote patient management. Patients will be randomized to remote patient management with VIRTUES versus usual care, and will be stratified by RemoteView vs no RemoteView utilization, as well as by center.

Conditions

  • Cardiac Arrhythmia

Interventions

  • Remote Patient ManagementDevice

    1. Transmissions will occur at six monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic. 2. All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years. 3. Patients will be contacted by phone at 6 months and 12 months to document their current health status (change in cardiovascular medications, any cardiovascular hospitalizations, in-clinic device checks, or any new cardiovascular testing completed since the last visit) 4. VIRTUES access

  • Standard of CareDevice

    No intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to major adverse cardiac event (primary safety outcome)Time frame: 18 months
  2. Time to a device-detected event (primary efficacy outcome)Time frame: 18 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Foothills Hospital

    Calgary, Alberta, Canada

  • Victoria Cardiac Arrhythmia Trials

    Victoria, British Columbia, Canada

  • St. Boniface Hospital

    Winnipeg, Manitoba, Canada

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.